ArticleOncology letters2025
Risks of haematological malignancies in patients treated for solid tumours associated with the use of pegylated granulocyte colony-stimulating factors: A single centre study since 2005.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of pegylated granulocyte colony-stimulating factors (PGCSFs), specifically pegfilgrastim and lipegfilgrastim, has been widely adopted to reduce the incidence of febrile neutropenia in patients undergoing chemotherapy. However, concerns regarding the long-term safety of PGCSFs, particularly the risk of secondary haematological malignancies, remain. The present study aimed to evaluate the incidence of secondary haematological malignancies in patients treated for solid tumours with PGCSFs at a single institution from 2005 to 2019. A retrospective analysis was conducted using an electronically managed database of 1,577 patients who received PGCSFs during chemotherapy for solid tumours. Patients with a history of any granulocyte or granulocyte-macrophage colony-stimulating factor administered prior to PGCSF were excluded. The incidence of secondary malignancies was assessed from the first application of PGCSF until the last patient contact, with a maximum follow-up time until December 2023. Among the evaluated cohort of 1,577 patients with the median follow-up time of 4.75 (0.0-18.1) years, respectively, with 757 (36.4%) patients followed-up for ≥5 years and 203 (18.1%) patients for ≥10 years; 7 (0.44%) patients were diagnosed with secondary haematological malignancies, including myelodysplastic syndrome in 2 patients, multiple myeloma in 3 patients and non-Hodgkin lymphoma in 2 patients. The present study findings demonstrated that the long-term use of PGCSFs in patients treated for solid tumours does not substantially increase the risk of secondary haematological malignancies, which supports their safety profile in clinical practice. However, a longer follow-up is necessary to further evaluate the safety of PGCSFs, particularly for biosimilars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.